Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Activated ClpP kills persisters and eradicates a chronic biofilm infection.
Conlon BP, Nakayasu ES, Fleck LE, LaFleur MD, Isabella VM, Coleman K, Leonard SN, Smith RD, Adkins JN, Lewis K. Conlon BP, et al. Among authors: isabella vm. Nature. 2013 Nov 21;503(7476):365-70. doi: 10.1038/nature12790. Epub 2013 Nov 13. Nature. 2013. PMID: 24226776 Free PMC article.
Pseudomonas aeruginosa biofilms in disease.
Mulcahy LR, Isabella VM, Lewis K. Mulcahy LR, et al. Among authors: isabella vm. Microb Ecol. 2014 Jul;68(1):1-12. doi: 10.1007/s00248-013-0297-x. Epub 2013 Oct 6. Microb Ecol. 2014. PMID: 24096885 Free PMC article. Review.
Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study.
Puurunen MK, Vockley J, Searle SL, Sacharow SJ, Phillips JA 3rd, Denney WS, Goodlett BD, Wagner DA, Blankstein L, Castillo MJ, Charbonneau MR, Isabella VM, Sethuraman VV, Riese RJ, Kurtz CB, Brennan AM. Puurunen MK, et al. Among authors: isabella vm. Nat Metab. 2021 Aug;3(8):1125-1132. doi: 10.1038/s42255-021-00430-7. Epub 2021 Jul 22. Nat Metab. 2021. PMID: 34294923 Clinical Trial.
Publisher Correction: Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study.
Puurunen MK, Vockley J, Searle SL, Sacharow SJ, Phillips JA 3rd, Denney WS, Goodlett BD, Wagner DA, Blankstein L, Castillo MJ, Charbonneau MR, Isabella VM, Sethuraman VV, Riese RJ, Kurtz CB, Brennan AM. Puurunen MK, et al. Among authors: isabella vm. Nat Metab. 2022 Sep;4(9):1214. doi: 10.1038/s42255-022-00635-4. Nat Metab. 2022. PMID: 35974248 No abstract available.
Improvement of a synthetic live bacterial therapeutic for phenylketonuria with biosensor-enabled enzyme engineering.
Adolfsen KJ, Callihan I, Monahan CE, Greisen PJ, Spoonamore J, Momin M, Fitch LE, Castillo MJ, Weng L, Renaud L, Weile CJ, Konieczka JH, Mirabella T, Abin-Fuentes A, Lawrence AG, Isabella VM. Adolfsen KJ, et al. Among authors: isabella vm. Nat Commun. 2021 Oct 28;12(1):6215. doi: 10.1038/s41467-021-26524-0. Nat Commun. 2021. PMID: 34711827 Free PMC article.
An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans.
Kurtz CB, Millet YA, Puurunen MK, Perreault M, Charbonneau MR, Isabella VM, Kotula JW, Antipov E, Dagon Y, Denney WS, Wagner DA, West KA, Degar AJ, Brennan AM, Miller PF. Kurtz CB, et al. Among authors: isabella vm. Sci Transl Med. 2019 Jan 16;11(475):eaau7975. doi: 10.1126/scitranslmed.aau7975. Sci Transl Med. 2019. PMID: 30651324 Clinical Trial.
An engineered bacterial therapeutic lowers urinary oxalate in preclinical models and in silico simulations of enteric hyperoxaluria.
Lubkowicz D, Horvath NG, James MJ, Cantarella P, Renaud L, Bergeron CG, Shmueli RB, Anderson C, Gao JR, Kurtz CB, Perreault M, Charbonneau MR, Isabella VM, Hava DL. Lubkowicz D, et al. Among authors: isabella vm. Mol Syst Biol. 2022 Mar;18(3):e10539. doi: 10.15252/msb.202110539. Mol Syst Biol. 2022. PMID: 35253995 Free PMC article.
26 results